Study guide

2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD

BONENT Certified Hemodialysis Nurse CHN

Track your progress as you read

Finished sections get a check mark.

1 Exam Orientation

1.1 Current CHN Exam Facts and Study Strategy

2 Chapter 1: Renal Anatomy, Physiology & CKD Pathophysiology

2.1 Nephron Physiology & Endocrine Functions 2.2 Acute Kidney Injury & Chronic Kidney Disease Staging 2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD

3 Chapter 2: CKD-MBD, Uremia & Clinical Manifestations

3.1 CKD-Mineral and Bone Disorder (CKD-MBD) 3.2 Uremic Syndrome & Multi-System Complications 3.3 Dialysis Patient Education & Nutritional Management

4 Individualized Nursing Care

4.1 Nursing Assessment, Planning and Evaluation 4.2 Treatment Records and Safe Handoffs 4.3 Psychosocial Assessment, Counseling and Referral

5 Chapter 3: Principles of Hemodialysis & Dialysate Chemistry

5.1 Transport Mechanisms: Diffusion, Convection & Ultrafiltration 5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux 5.3 Dialysate Composition & Concentrate Formulations 5.4 Hemodialysis Adequacy: Urea Kinetics, Kt/V & URR

6 Chapter 4: Vascular Access: Fistulas, Grafts & Catheters

6.1 Arteriovenous Fistulas & Arteriovenous Grafts 6.2 Physical Examination, Surveillance & Monitoring of Access 6.3 Central Venous Catheters & CDC Infection Prevention

7 Chapter 5: Cannulation Practice & Access Complications

7.1 Cannulation Techniques: Rope-Ladder, Buttonhole & Needle Sizing 7.2 Vascular Access Stenosis, Thrombosis & Steal Syndrome 7.3 Access Infiltration, Pseudoaneurysms & Hemorrhage Management

8 Chapter 6: Hemodialysis Treatment Delivery & Circuit Monitoring

8.1 Pre-Dialysis Assessment, Target Dry Weight & UFR Limits 8.2 Extracorporeal Circuit Setup, Priming & Safety Alarms 8.3 Anticoagulation Management: Heparin Protocols & Citrate 8.4 Treatment Termination, Hemostasis & Post-Dialysis Assessment

9 Equipment and Laboratory Skills

9.1 Ancillary Equipment and Bedside Safety 9.2 Blood Sampling, Laboratory Trends and Critical Results

10 Chapter 7: Acute Intradialytic Complications & Emergencies

10.1 Intradialytic Hypotension & Muscle Cramping 10.2 Dialysis Disequilibrium Syndrome & Neurological Events 10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B) 10.4 Critical Emergencies: Air Embolism, Hemolysis & Blood Loss

11 Extended and Acute Treatment

11.1 Sequential UF, Hemofiltration and Hemoperfusion 11.2 Acute Kidney Injury and High-Risk Dialysis Initiation

12 Chapter 8: Nephrology Pharmacology in Hemodialysis

12.1 Anemia Management: ESAs & Intravenous Iron Therapy 12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics 12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing

13 Home and Peritoneal Dialysis

13.1 Home Dialysis Selection and Adult Learning 13.2 Home Setup, Monitoring and Emergency Readiness 13.3 Peritoneal Dialysis Principles and Nursing Care

14 Kidney Transplantation

14.1 Transplant Benefits, Burdens and Modality Counseling 14.2 Transplant Indications, Contraindications and Referral 14.3 Pretransplant Workup and Waiting-List Coordination 14.4 Immunosuppressants, Interactions and Patient Teaching 14.5 Returning to Dialysis After Graft Failure 14.6 New-Graft Monitoring and Urgent Changes

15 Chapter 9: Water Treatment Systems & Dialyzer Reprocessing

15.1 AAMI/ISO Water Treatment Architecture & Components 15.2 Chemical Contaminant Monitoring & Total Chlorine Testing 15.3 Microbiological Standards, Endotoxin Surveillance & Sampling 15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety

16 Clinical Unit Management

16.1 Evaluating Dialysis Technology and Supplies 16.2 Staffing, Personnel Policies and Standards of Care

17 Chapter 10: Supervision, Administration & Professional Practice

17.1 RN Delegation, Technician Supervision & Nurse Practice Acts 17.2 CMS Conditions for Coverage & Interdisciplinary Care Planning 17.3 Dialysis Unit Infection Control & Environmental Safety 17.4 Quality Improvement (ESRD QIP), Ethics & Palliative Care

18 Professional Development

18.1 Professional Literature, Organizations and Continuing Learning 18.2 Research Design, Implementation and Evidence Interpretation 18.3 Staff Training, Competency and Remediation

19 Environmental Hazards and Emergency Planning

19.1 Chemical Agents, Disinfection and Exposure Control 19.2 Biological Hazards and Occupational Injury Response 19.3 Fire, Threats and Power or Water Interruptions

2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD

Key Takeaways Explain This Topic AI

A normal ECG does not exclude dangerous hyperkalemia; laboratory and clinical assessment remain essential.

Calcium stabilizes myocardium; insulin shifts potassium; dialysis removes potassium from the body.

Insulin treatment in kidney failure requires continued glucose surveillance for delayed hypoglycemia.

Calcium, phosphorus and PTH trends are assessed together; the calcium-phosphorus product is not a calciphylaxis diagnostic test.

Last updated: October 2026

Fluid, Electrolyte & Acid-Base Imbalances in ESRD

In end-stage renal disease (ESRD), total loss of functioning nephrons impairs homeostatic regulation of fluid volume, electrolyte concentrations, and systemic pH. Between intermittent hemodialysis treatments, dietary fluid, potassium, phosphate, and metabolic acids accumulate. Mastering the physiological principles of hyperkalemia, mineral disorders, and metabolic acidosis allows hemodialysis nurses to anticipate decompensation and manage emergency interventions effectively.

Hyperkalemia: Electrophysiology & ECG Progression

Potassium is the primary intracellular cation (~3,000–4,000 mEq total). Approximately 98% resides inside cells (~140 mEq/L), maintained by the basolateral N a + / K + Na^+/K^+ N a + / K + -ATPase pump, while 2% resides in extracellular fluid (normal: 3.5 to 5.0 mEq/L ). Normal kidneys excrete 90% to 95% of daily intake. In anuric ESRD, clearance is lost, causing hyperkalemia ( K + > 5.0 mEq/L K^+ > 5.0\text{ mEq/L} K + > 5.0 mEq/L ) .

Cellular Electrophysiology of Cardiotoxicity

Ventricular resting membrane potential ( R M P RMP RMP ) is determined by the transcellular potassium ratio via the Nernst equation: E K = − 61.5 log ⁡ 10 ( [ K + ] in / [ K + ] out ) E_K = -61.5 \log_{10}([K^+]_{\text{in}}/[K^+]_{\text{out}}) E K ​ = − 61.5 lo g 10 ​ ([ K + ] in ​ / [ K + ] out ​ ) . Elevated extracellular potassium shifts R M P RMP RMP to a less negative, partially depolarized state (e.g., − 90 mV -90\text{ mV} − 90 mV toward − 70 mV -70\text{ mV} − 70 mV ):

Fast Sodium Channel Inactivation : Causes voltage-gated inactivation of fast N a + Na^+ N a + channels ( N a v 1.5 Na_v1.5 N a v ​ 1.5 ), depressing Phase 0 upstroke velocity ( V max ⁡ V_{\max} V m a x ​ ) and slowing conduction through atria, AV node, and ventricles.

Increased extracellular potassium alters myocardial resting potential, conduction and repolarization; IKr is a rapid delayed-rectifier current, not an inward-rectifier channel.

ECG Findings and Their Limits

Hyperkalemia may produce peaked T waves, PR prolongation, loss of P waves, QRS widening or a sine-wave pattern. These changes do not occur at dependable potassium bands or in a required sequence. A normal ECG does not exclude dangerous hyperkalemia. Evaluate a critical result promptly, consider hemolysis of the specimen, repeat testing when indicated, and do not delay emergency treatment in an unstable patient while pursuing confirmation. Compare baseline conduction disease and medication effects as well as the measured potassium.

Acute Hyperkalemia Management Protocol: The Three Tiers

The three aims are cardiac protection when indicated, temporary intracellular shifting and definitive removal. In a severe emergency these measures are coordinated promptly; they are not a reason to postpone removal until every preceding drug is completed.

Tier 1: Immediate Myocardial Membrane Stabilization

Intravenous calcium: Use the ordered emergency formulation and dose, with ECG monitoring. Gluconate and chloride are not interchangeable gram-for-gram in elemental calcium; calcium stabilizes myocardium without removing potassium.

Tier 2: Rapid Intracellular Potassium Shifting

Insulin with glucose: Administer through the ordered hyperkalemia protocol; assess baseline glucose and continue repeated monitoring for delayed hypoglycemia, commonly at least six hours in kidney failure. Dose and glucose support are individualized.

Nebulized albuterol: The ordered high-dose emergency regimen shifts potassium through beta-2 stimulation. Response varies, so it is adjunctive therapy rather than reliable monotherapy. Observe heart rate and symptoms and reassess measured potassium.

Sodium bicarbonate: Not routinely recommended for acute potassium lowering. The prescriber considers acid-base status, sodium/fluid burden and the clinical situation; do not apply a universal IV-push dose or pH cutoff.

Tier 3: Definitive Total Body Potassium Removal

Urgent hemodialysis: Removes potassium from the body. The amount and rate depend on the serum-to-dialysate gradient, flow, duration, access and redistribution. Confirm the individualized bath and ECG monitoring; do not independently select a very low-potassium bath.

Potassium binders: Their onset, sodium load and gastrointestinal warnings differ. They do not replace urgent myocardial stabilization and definitive removal in a life-threatening emergency.

Calcium, Phosphorus and Acid-Base Decisions

Reduced phosphate excretion and reduced calcitriol production contribute to secondary hyperparathyroidism. Interpret calcium, phosphorus and parathyroid hormone together over time. A calcium-phosphorus product is a historical teaching measure; it is not the current sole treatment target or a diagnostic test for calciphylaxis. Painful, evolving skin lesions require urgent evaluation even without a markedly elevated product. Ionized calcium is especially useful when albumin or acid-base status makes total calcium difficult to interpret.

Metabolic acidosis develops when renal acid excretion and bicarbonate regeneration fall. It may contribute to muscle catabolism, bone buffering and increased extracellular potassium. The potassium response to a pH change varies with the underlying acid, insulin status, cellular injury and renal clearance. The shortcut that every 0.1 pH fall raises potassium by 0.6 mEq/L is unreliable and must not be used to predict a safe potassium concentration or calculate treatment.

In nondialysis CKD, KDIGO 2024 advises considering treatment to prevent clinically important acidosis, giving serum bicarbonate below 18 mmol/L in adults as an example; this is not a universal dialysis prescription. During hemodialysis, the clinician individualizes dialysate buffer and follows pre- and post-treatment clinical effects. Excessive alkalinization can lower ionized calcium and potassium, increasing cramps or arrhythmia risk. Persistent low bicarbonate requires review of adequacy, nutrition, gastrointestinal loss and the delivered prescription.

For severe hyperkalemia, ordered intravenous calcium stabilizes myocardium without removing potassium. Insulin with glucose and inhaled beta agonists shift potassium temporarily; dialysis removes it. Use the emergency protocol’s formulation and dose, monitor ECG and glucose, and recognize delayed hypoglycemia in kidney failure. Glucose surveillance continues for the protocol-specified period, commonly at least six hours after insulin, rather than stopping after the first normal reading. Sodium bicarbonate is not a routine substitute for these treatments; its use depends on acidosis and clinical context. Potassium binders have formulation-specific effects and warnings and must not delay emergency stabilization or dialysis.

Sources checked 2026-10-11: KDIGO CKD and UK Kidney Association hyperkalemia guideline, July 2026 update